Fairmount’s $17 Share Buy Signals Confidence in Viridian’s TED Pipeline
Fairmount’s $17.00 buy of 1.18 M Viridian shares signals institutional confidence that the $342 M capital raise will fuel safe, efficacious Phase 3 trials for the company’s promising TED therapy, VT‑101, and help secure a breakthrough‑therapy design…
5 minutes to read